CheezhengTTM(SZ:002287)2023-11-03 16:00Corporate Governance - The company maintains complete control over its assets, with no instances of asset occupation by controlling shareholders or other shareholders[8]. - The company operates independently from its controlling shareholders, with a complete organizational structure and the ability to make independent financial decisions[7]. - The supervisory board consists of 4 members, including 2 employee supervisors, ensuring compliance with legal requirements[6]. - The company has established an independent financial department and a financial management system, ensuring independent financial operations[10]. - The company has a clear and independent property relationship with its controlling shareholders, with no guarantees provided for shareholders' debts[8]. - The company has no competition with its controlling shareholders, as its business activities are entirely independent[7]. - The company has implemented a robust internal control system in accordance with relevant laws and regulations[4]. - The company has actively participated in shareholder meetings and has adhered to the required procedures for supervisory board meetings[6]. - The company has not raised any objections to matters discussed in the board meetings during the reporting period[55]. Management and Remuneration - The company reported a total shareholding of 444,031 shares for the president, Liu Kailie, at the end of the period[24]. - The company has not experienced any changes in shareholding for the board members and supervisors during the reporting period[25]. - The chairman, Lei Jufang, has been in position since October 8, 2007, and is set to serve until May 13, 2024[26]. - The company has a total of 266,418 shares held by the Vice President of Operations, Xiao Jianqin, at the end of the period[24]. - The company has a total of 177,612 shares held by Vice President Wang Zhiqiang at the end of the period[24]. - The company has a total of 192,945 shares held by Vice President Li Jun at the end of the period[24]. - The company has a total of 133,209 shares held by Chief Scientist Chen Weiwu at the end of the period[24]. - The company has maintained a stable management team with no resignations or dismissals reported during the period[25]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 13.9881 million CNY[33]. - Liu Kailie, the President and Director, received a pre-tax remuneration of 2.8195 million CNY[33]. - The company has 7 directors, including 3 independent directors, and 4 supervisors[33]. - The performance evaluation for senior management is based on company performance and individual achievements, with annual target assessment agreements signed[33]. - The independent directors' remuneration standards are determined by the shareholders' meeting, covering reasonable expenses incurred while exercising their duties[33]. - The company has established a Nomination and Remuneration Committee to review and formulate remuneration policies for directors and senior management[33]. - The company’s operational vice president, Xiao Jianqin, received a pre-tax remuneration of 1.2712 million CNY[33]. - The total number of senior management personnel is 9, with one serving concurrently as a director[33]. - The remuneration for the independent director, Guo De'an, was 46,600 CNY[33]. - The company has a performance-based remuneration system that aligns with its operational results[33]. Financial Performance - The company reported a total revenue of 1.2 billion yuan for the fiscal year 2022, representing a year-over-year increase of 15%[39]. - The net profit attributable to shareholders for the fourth quarter was RMB 112,865,167.25, reflecting a decrease from the third quarter's RMB 127,221,135.64[117]. - The company reported a total net profit attributable to shareholders of RMB 472,408,229.26 for the entire year of 2022, marking a year-on-year increase of 15%[117]. - The gross profit margin for the year was reported at 60%, indicating strong profitability in its core business operations[1]. - The net profit attributable to shareholders for 2022 was ¥472,408,229.26, a decrease of 34.01% from ¥715,876,201.47 in 2021[137]. - The net profit excluding non-recurring gains and losses was ¥440,018,192.00, up 27.57% from ¥344,932,156.80 in 2021[137]. - The basic earnings per share for 2022 was ¥0.8919, down 34.14% from ¥1.3542 in 2021[137]. - The total assets attributable to shareholders at the end of 2022 were ¥5,886,644,252.44, an increase of 5.73% from ¥5,567,753,848.57 at the end of 2021[137]. Market Expansion and Product Development - The company is actively involved in various associations and has received multiple honors for its contributions to the industry[26]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by 2025[39]. - New product launches included two innovative herbal medicine products, projected to contribute an additional 200 million yuan in revenue[39]. - The company plans to invest 100 million yuan in digital marketing initiatives to boost brand awareness[39]. - The company aims to achieve the strategic goal of being the "first in external pain relief and first in the Tibetan medicine market" through a multi-product marketing approach and modernization of Tibetan medicine[66]. - In 2023, the company initiated a new chapter in multi-product marketing, focusing on consolidating market share for core products and accelerating growth in key varieties such as Tie Bang Chui Pain Relief Ointment and Qing Peng Ointment[66]. - The company plans to expand its product cluster in seven major therapeutic areas, including respiratory, pediatrics, gynecology, digestion, cardiovascular, and neurology, with specific products targeting unmet clinical needs[69]. - The company is focusing on digital marketing transformation and expanding e-commerce platform sales to adapt to consumer trends[157]. - The company is enhancing its distribution channels, particularly focusing on B2C and O2O models to improve customer reach[1]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[1]. Research and Development - Research and development expenses increased by 30% to 150 million yuan, focusing on new drug formulations[39]. - The company is committed to enhancing its research and development capabilities, focusing on the modernization of Tibetan medicine and the development of new products based on clinical needs[70]. - The company has established a strong R&D platform for Tibetan medicine products, ensuring quality and safety throughout the product lifecycle[70]. - The company has optimized its R&D system, enhancing product development capabilities and accelerating product launches[172]. - The company completed the key research tasks of the national key R&D project on Tibetan medicine, demonstrating significant advantages of its products in treating acute ischemic stroke compared to placebo[197]. - The clinical research on Baipai Ointment for diabetic peripheral neuropathy showed significant improvement in patients' symptoms of numbness and pain[197]. - The clinical study results indicated that Baipai Ointment significantly alleviates pain and improves function in patients with lumbar disc herniation[197]. - The company published a total of 24 papers during the reporting period, including 5 SCI articles[197]. - The company completed the Phase III clinical study of Cuotang Granules, showing good efficacy and safety in treating common cold symptoms[198]. - The production line for Cuotang Granules has been licensed, ensuring smooth progress for commercialization[198]. Sustainability and Compliance - The company is committed to complying with national policies and enhancing its product's clinical evidence chain to ensure sustainable business development[63]. - The company is committed to sustainable development practices, being recognized as a national green demonstration factory[188]. - The company emphasizes sustainable resource development and quality standard improvement in its research tasks[131]. - The company has established wild nurturing and artificial planting bases for Tibetan medicinal materials[163]. - The company has established a cultivation area of 100 acres for medicinal materials as part of a national major project for the cultivation demonstration base of Tibetan medicinal materials[174].